Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer

• Main Authors: Wang BY (Author), Liu QY (Author), Cao J (Author), Chen JW (Author), Liu ZS (Author)
• Format: Book
• Published: Dove Medical Press, 2016-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1177-8881
• Keywords: Selective CDK7 inhibitor; Gastric cancer; BS-181; Anti-cancer activities; Therapeutics. Pharmacology; RM1-950
• Source: Drug Design, Development and Therapy, Vol 2016, Iss Issue 1, Pp 1181-1189 (2016)

Bo-Yong Wang, Quan-Yan Liu, Jun Cao, Ji-Wei Chen, Zhi-Su Liu Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China Abstract: Cyclin-dependent kinase (CDK) family members have been considered as attractive therapeutic targets for cancer. In this study, we aim to investigate the anticancer effects of a selective CDK7 inhibitor, BS-181, in gastric cancer (GC) cell line. Human GC cells (BGC823) were cultured with or without BS-181 at different concentrations for 24–72 hours. BS-181 significantly reduced the activity of CDK7 with downregulation of cyclin D1 and XIAP in GC cells. Treatment with BS-181 induced cell cycle arrest and apoptosis. The expression of Bax and caspase-3 was significantly increased, while Bcl-2 expression was decreased in cells treated with BS-181. In addition, the inhibition of CDK7 with BS-181 resulted in reduced rates of proliferation, migration, and invasion of gastric cells. Those results demonstrated the anticancer activities of selective CDK7 inhibitor BS-181 in BGC823 cells, suggesting that CDK7 may serve as a novel therapeutic target or the treatment of GC. Keywords: selective CDK7 inhibitor, gastric cancer, BS-181, anticancer activities